Clinical Trial Update: "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluates whether pioglitazone can reverse defects in mitochondrial biogenesis in patients with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Pennington Biomedical Research Center | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED